Teva Pharmaceutical Industries (TEVA) Gross Margin (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Gross Margin for 18 consecutive years, with 51.98% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin rose 164.0% year-over-year to 51.98%; the trailing twelve-month figure through Jun 2026 stood at 52.47% (down 144.0% YoY), and the FY2025 full-year result was 51.79%, up 305.0% from the prior year.
• Gross Margin rose to 51.98% in Q2 2026 per TEVA's latest filing, from 49.52% in the prior quarter.
• Across five years, Gross Margin topped out at 73.14% in Q4 2024 and bottomed at 43.21% in Q1 2023.
• Historically, Gross Margin has averaged 50.24% across 5 years, with a median of 48.42% in 2024.
• The sharpest annual moves came in 2024 and 2025: Gross Margin surged 1893 bps in 2024, then slumped 1676 bps in 2025.
• Over 5 years, Gross Margin stood at 45.57% in 2022, then grew by 19 bps to 54.21% in 2023, then surged by 35 bps to 73.14% in 2024, then fell by 23 bps to 56.38% in 2025, then fell by 8 bps to 51.98% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 51.98%, 49.52%, and 56.38% for Q2 2026, Q1 2026, and Q4 2025 respectively.